We wanted to find out if pre-emptive treatment aimed at transplant recipients who are at risk of developing CMV disease, rather than administering universal prophylaxis, including those who are ...
First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with ...